Opdivo vs Revlimid
Side-by-side cost comparison based on Medicare Part D data
Opdivo
Nivolumab
Manufactured by Bristol-Myers Squibb
Revlimid
Lenalidomide
Manufactured by Bristol-Myers Squibb
Revlimid costs 19% less per claim than Opdivo ($12,786.00 vs $15,821.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Opdivo | Revlimid |
|---|---|---|
| Avg Cost Per Claim | $15,821.00 | $12,786.00 |
| Total Medicare Spending | $5.1B | $7.8B |
| Total Beneficiaries | 66,000 | 58,000 |
| Total Claims | 324,000 | 612,000 |
| Annual Cost/Patient | $77,667.00 | $134,914.00 |
| Year-over-Year Change | +15.8% | -3.4% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Mar 15, 2027 |
| Manufacturer | Bristol-Myers Squibb | Bristol-Myers Squibb |
| Condition | Cancer | Cancer |
| Generic Name | Nivolumab | Lenalidomide |
Opdivo vs Revlimid: What the Data Shows
Opdivo (Nivolumab) and Revlimid (Lenalidomide) are both used to treat cancer. Based on Medicare Part D data, Revlimid costs $12,786.00 per claim, which is 19% less than Opdivo at $15,821.00 per claim.
Medicare spent $5.1B on Opdivo and $7.8B on Revlimid. In terms of patient reach, Opdivo serves more beneficiaries (66,000 vs 58,000).
Year-over-year spending changed +15.8% for Opdivo and -3.4% for Revlimid. Opdivo saw significant spending growth, suggesting increased utilization or price increases.
Opdivo has a generic available, while Revlimid remains brand-only until its patent expires Mar 15, 2027.
Frequently Asked Questions
Revlimid is cheaper at $12,786.00 per claim, compared to $15,821.00 for Opdivo. That makes Revlimid about 19% less expensive per claim based on Medicare Part D data.
Yes, both Opdivo and Revlimid are used to treat cancer. Your doctor can help determine which medication is more appropriate for your specific situation.
Opdivo has a generic version (Nivolumab) available, which is typically much cheaper. Revlimid is currently brand-only, with patent expiring Mar 15, 2027.
Medicare Part D spent $5.1B on Opdivo covering 66,000 beneficiaries, and $7.8B on Revlimid covering 58,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.